Is macituximab/magenex a hormonal drug?

Margetuximab is not a hormonal drug. It is an engineered monoclonal antibody that targets anti-HER2. It is a biological agent, not a hormone treatment drug in the traditional sense. To determine whether a drug is a hormone, one needs to consider its mechanism of action, molecular structure and targeting system. The mode of action of margetuximab is significantly different from that of hormonal drugs, so it can be clearly said that it is not a hormonal drug.

Hormonal drugs usually affect tumor growth by regulating the endocrine system or simulating the effects of hormones in the body, such as estrogen blockers, progesterone drugs, etc. The mechanism of margetuximab is completely different. Its target is HER2, not the endocrine system. It does not participate in the regulation of hormone levels in the body and does not affect estrogen receptors or other endocrine pathways.

As an engineered antibody, margetuximab works in two ways: first, inhibiting the HER2 signaling pathway and reducing the growth stimulation of tumor cells; second, enhancing the body's immune cells' ability to recognize and eliminate tumor cells. This is similar to traditional HER2 monoclonal antibodies, but its Fc engineering design allows the immune system to be more actively involved and can more effectively mobilize immune cells such as NK cells.

Therefore, from the perspective of drug classification, molecular structure, mechanism of action, and treatment targets, margetuximab is not a hormonal drug, but a targeted antibody drug, which is closely related to immunotherapy. The treatment plan for some breast cancer patients will involve both hormone therapy and HER2-targeted therapy, which makes some patients easily mistakenly believe that HER2-targeted drugs are also hormone drugs. However, hormone receptor positivity (HR+) and HER2 positivity (HER2+) are two independent biomarker systems, so the two drugs are not equivalent.

Hormonal drugs act on the endocrine system, while HER2 drugs act on cell growth signaling pathways. The two drugs often appear in cancer treatment programs at the same time due to the "requirement for combined treatment", but they are not the same drug properties.

Reference materials:https://www.margenza.com/